ENLIBI Trademark
ENLIBI is a USPTO trademark filed by Teva Pharmaceuticals International GmbH. Status: Pending.
Trademark Facts
| Mark | ENLIBI |
|---|---|
| Serial Number | 99374409 |
| Status | Pending |
| Filing Date | 2025-09-04 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Teva Pharmaceuticals International GmbH |
| Attorney of Record | Lori Wolfe |
| Prosecution Events | 21 |
| Latest Event | NOAM on 2026-04-28 |
Goods & Services
Class 005: Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, gastro-intestinal diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations.
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-04-28 | Notice of Allowance | ENA |
| 2026-03-03 | OG Publication Confirmation | PB3 |
| 2026-02-25 | Notice of Publication | PB1 |
| 2026-02-25 | Notification of Notice of Publication | EB4 |
| 2026-02-06 | Amendment and Mail Process Complete | AMC |
| 2026-02-05 | Response to Office Action | ROA |
USPTO Refusals on Record
- entity_clarification